PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors

Completed · Phase 1

Conditions studied: Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: Drugs used in chemotherapy, such as PR-104, docetaxel, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of PR-104 when given together with docetaxel or gemcitabine in treating patients with solid tumors.

Key facts

Study ID

NCT00459836

Run by

Proacta, Incorporated

People needed

42

Starts

2007-02-01

Last updated by the study team

2011-03-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Proacta, Incorporated — San Diego, California, United States
• University of Auckland Cancer Center — Auckland, New Zealand
• Waikato Hospital — Hamilton, New Zealand

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.